Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.-论文-万方医学网

作者： Gérald,Simonneau ^[1] ; Lewis J,Rubin ^[2] ; Nazzareno,Galiè ^[3] ; Robyn J,Barst ^[4] ; Thomas R,Fleming ^[5] ; Adaani,Frost ^[6] ; Peter,Engel ^[7] ; Mordechai R,Kramer ^[8] ; Marjana,Serdarevic-Pehar ^[9] ; Gary R,Layton ^[10] ; Olivier,Sitbon ^[11] ; David B,Badesch ^[12] ; PACES Study Group

作者单位： University Paris-Sud, National Reference Center for Severe Pulmonary Hypertension, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: gerald.simonneau@bct.aphp.fr. ^[1] Department of Medicine, University of California at San Diego, La Jolla, California. ^[2] Institute of Cardiology, Bologna University Hospital, Bologna, Italy. ^[3] Division of Pediatric Cardiology, Columbia University, New York, New York. ^[4] Department of Biostatistics, University of Washington, Seattle, Washington. ^[5] Department of Medicine, Section of Pulmonary and Critical Care, Baylor College of Medicine, Houston, Texas. ^[6] Pulmonary Hypertension Program, The Christ Hospital, Cincinnati, Ohio. ^[7] Pulmonary Institute, Rabin Medical Center, Petah Tikva, Israel. ^[8] Pfizer Inc, New York, New York. ^[9] Worldwide Pharmaceutical Operations, Pfizer Ltd, Sandwich, Kent, United Kingdom. ^[10] University Paris-Sud, National Reference Center for Severe Pulmonary Hypertension, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. ^[11] Division of Pulmonary Sciences and Critical Care Medicine, and Cardiology Director, Pulmonary Hypertension Program, University of Colorado Denver, Denver, Colorado. ^[12]